Liquidia Corporation LQDA

Interstitial Lung Disease Market to Witness Accelerated Growth at a CAGR of 8.7% During the Forecast Period (2026–2036) Due to the Launch of Emerging Therapies | DelveInsight

GlobeNewswire Inc. · 106d ago

Liquidia's Chairman Sold Company Shares Worth $2.5 Million. Should Investors Avoid the Stock?

The Motley Fool · 109d ago

The Chief Commercial Officer of Liquidia (LQDA) Sold 80,000 Shares for $2.8M

The Motley Fool · 117d ago

Liquidia to Present Clinical Data from ASCENT Trial at the CHEST 2025 Annual Meeting

Benzinga · 297d ago

Pulmonary Hypertension associated with Interstitial Lung Disease Market to Witness Upsurge in Growth During the Forecast Period (2025–2034) | DelveInsight

GlobeNewswire Inc. · 343d ago

U.S. FDA Approves Liquidia’s YUTREPIA™ (treprostinil) Inhalation Powder for Patients with Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated with Interstitial Lung Disease (PH-ILD)

GlobeNewswire Inc. · 426d ago

Liquidia Corporation Provides Update on Litigation Filed by United Therapeutics

GlobeNewswire Inc. · 437d ago

District Court Dismisses Dispute Filed by United Therapeutics Against Liquidia

GlobeNewswire Inc. · 447d ago

Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025

GlobeNewswire Inc. · 498d ago

Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

GlobeNewswire Inc. · 514d ago

Evolving Landscape of Cardiology Segment: Key Market Insights of Latest Published Rare Cardiovascular Diseases Report — Giant-Cell Arteritis, Pulmonary Arterial Hypertension, and Restrictive Cardiomyopathy | DelveInsight

GlobeNewswire Inc. · 555d ago

United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics’ Patent

GlobeNewswire Inc. · 654d ago

Liquidia and Pharmosa Biopharm Expand Collaboration to Develop Sustained Release Inhaled Treprostinil (L606)

GlobeNewswire Inc. · 659d ago

Liquidia corp chief medical officer sells $18.4k in stock - Investing.com

Investing.com · 738d ago

Liquidia Corp executive sells shares worth over $19,000 - Investing.com

Investing.com · 738d ago

Voip-pal director Kevin Williams sells shares worth $19,234 By Investing.com - Investing.com

Investing.com · 738d ago

Forecasting The Future: 5 Analyst Projections For Liquidia

Benzinga · 758d ago

Liquidia Announces Poster Presentations at the 7th World Symposia on Pulmonary Hypertension (WSPH)

GlobeNewswire Inc. · 765d ago

7 Analysts Have This To Say About Liquidia

Benzinga · 780d ago

Liquidia Stock: A Deep Dive Into Analyst Perspectives (6 Ratings)

Benzinga · 799d ago

MannKind Outperforms As Tyvaso DPI Captures Market Share

Seeking Alpha · 799d ago

Down -11.26% in 4 Weeks, Here's Why You Should You Buy the Dip in Liquidia Technologies (LQDA)

Zacks Investment Research · 800d ago

Liquidia Corporation Reports First Quarter 2024 Financial Results and Provides Corporate Update

GlobeNewswire Inc. · 801d ago

Deciphera Pharmaceuticals, Inc. (DCPH) Reports Q1 Loss, Misses Revenue Estimates

Zacks Investment Research · 804d ago

Liquidia Announces Poster Presentation at the American Thoracic Society (ATS) 2024 International Conference on Its Open-Label Safety Study of L606 (Liposomal Treprostinil) in Patients with PAH and PH-ILD

GlobeNewswire Inc. · 804d ago